Sensei Biotherapeutics, Inc.

NasdaqGM:SNSE Rapporto sulle azioni

Cap. di mercato: US$12.3m

Sensei Biotherapeutics Performance dei guadagni passati

Il passato criteri di controllo 0/6

Sensei Biotherapeutics's earnings have been declining at an average annual rate of -12.1%, while the Biotechs industry saw earnings growing at 19% annually.

Informazioni chiave

-12.1%

Tasso di crescita degli utili

103.6%

Tasso di crescita dell'EPS

Biotechs Crescita del settore17.0%
Tasso di crescita dei ricavin/a
Rendimento del capitale proprio-56.9%
Margine netton/a
Ultimo aggiornamento sui guadagni30 Jun 2024

Aggiornamenti sulle prestazioni recenti

Nessun aggiornamento

Recent updates

Is Sensei Biotherapeutics (NASDAQ:SNSE) In A Good Position To Deliver On Growth Plans?

Nov 03
Is Sensei Biotherapeutics (NASDAQ:SNSE) In A Good Position To Deliver On Growth Plans?

We Think Sensei Biotherapeutics (NASDAQ:SNSE) Needs To Drive Business Growth Carefully

Jul 02
We Think Sensei Biotherapeutics (NASDAQ:SNSE) Needs To Drive Business Growth Carefully

Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation

Mar 14
Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation

We're Hopeful That Sensei Biotherapeutics (NASDAQ:SNSE) Will Use Its Cash Wisely

Aug 14
We're Hopeful That Sensei Biotherapeutics (NASDAQ:SNSE) Will Use Its Cash Wisely

Sensei Biotherapeutics GAAP EPS of -$0.34 beats by $0.06

Aug 09

Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation

Apr 18
Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation

Sensei Biotherapeutics (NASDAQ:SNSE) Is In A Good Position To Deliver On Growth Plans

Nov 16
Sensei Biotherapeutics (NASDAQ:SNSE) Is In A Good Position To Deliver On Growth Plans

Ripartizione dei ricavi e delle spese

Come Sensei Biotherapeutics guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.


Storia dei guadagni e delle entrate

NasdaqGM:SNSE Ricavi, spese e utili (USD Millions )
DataRicaviGuadagniSpese G+ASpese di R&S
30 Jun 240-301418
31 Mar 240-321718
31 Dec 230-341918
30 Sep 230-392020
30 Jun 230-452227
31 Mar 230-462128
31 Dec 220-492030
30 Sep 220-461829
30 Jun 220-421726
31 Mar 220-411626
31 Dec 210-371622
30 Sep 210-331518
30 Jun 210-281315
31 Mar 210-231012
31 Dec 200-20811
30 Sep 200-23611
31 Dec 190-2148

Guadagni di qualità: SNSE is currently unprofitable.

Margine di profitto in crescita: SNSE is currently unprofitable.


Flusso di cassa libero e analisi degli utili


Analisi della crescita degli utili nel passato

Andamento degli utili: SNSE is unprofitable, and losses have increased over the past 5 years at a rate of 12.1% per year.

Accelerare la crescita: Unable to compare SNSE's earnings growth over the past year to its 5-year average as it is currently unprofitable

Guadagni vs Settore: SNSE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).


Rendimento del capitale proprio

ROE elevato: SNSE has a negative Return on Equity (-56.85%), as it is currently unprofitable.


Rendimento delle attività


Rendimento del capitale investito


Scoprire le aziende con forti performance passate